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THO/TREX is a conserved eukaryotic complex formed
by the core THO complex plus proteins involved in
mRNA metabolism and export such as Sub2 and Yra1.
Mutations in any of the THO/TREX structural genes
cause pleiotropic phenotypes such as transcription im-
pairment, increased transcription-associated recombi-
nation, and mRNA export defects. To assay the rele-
vance of THO/TREX complex in transcription, we
performed in vitro transcription elongation assays in
mutant cell extracts using supercoiled DNA templates
containing two G-less cassettes. With these assays, we
demonstrate that hpr1, tho2, and mft1 mutants of
the THO complex and sub2 mutants show significant
reductions in the efficiency of transcription elongation.
The mRNA expression defect of hpr1 mutants was not
due to an increase in mRNA decay, as determined by
mRNA half-life measurements and mRNA time course
accumulation experiments in the absence of Rrp6p ex-
oribonuclease. This work demonstrates that THO and
Sub2 are required for efficient transcription elongation,
providing further evidence for the coupling between
transcription and mRNA metabolism and export.
mRNA synthesis in eukaryotes is a multistep process medi-
ated by RNA polymerase II (RNAPII)1 and consists of three
major stages, i.e. initiation, elongation, and termination. Dur-
ing elongation, RNAPII has to overcome situations derived
from transient pausing caused by regulatory signals with the
help of transcriptional elongation factors. These factors associ-
ate with RNAPII to facilitate elongation through either partic-
ular DNA sequences or chromatin (1, 2). Among these factors,
there is functional evidence for roles in transcription elonga-
tion for TFIIS (3, 4), TFIIF (5, 6), human elongin (7), human
11-19 lysine-rich leukemia (ELL) (8), human FACT/yeast
Spt16-Pob3 (9–11), human DSIF/yeast Spt4-Spt5 (12, 13), hu-
man NELF (14), and the 19 S proteasome subunit (15). In
addition, there is a set of eukaryotic factors that might also
have an effect in transcription elongation. One such factor is
THO/TREX.
THO was identified in yeast as a four-protein complex
containing Tho2, Hpr1, Mft1, and Thp2 (16). Null mutations
in each of the genes encoding the subunits of THO confer
increased recombination between direct repeats, high levels
of plasmid and chromosome instability, and defects in gene
expression. This is particularly evident for long and GC-rich
DNA sequences such as lacZ (16–19). The observation that
transcription of some DNA sequences is impaired in THO
mutants and that hyper-recombination only occurs at ac-
tively transcribed sequences whose transcription is THO-de-
pendent suggests that transcription elongation is impaired in
these mutants (17, 19, 20). However, in contrast to mutants
of bona fide transcription elongation factors, THO mutants
show transcription-dependent genetic instability and are not
sensitive to 6-azauracil (6-AU) (17), a hallmark phenotype
associated with transcription elongation defects (21).
Recently, THO has been shown to be present in a larger
complex, termed TREX, together with components of the
mRNA export machinery such as Sub2 and Yra1 (22). In addi-
tion, sub2 and yra1 mutants show the same gene expression
defects and transcription-associated hyper-recombination as
those of the THO mutants (23, 24). This, together with the
mRNA export defect of THO mutants, the THO-like gene ex-
pression and recombination phenotypes of mutants of the
Mex67-Mtr2 mRNA export factor, and the ability of THO to
bind RNA in vitro, suggests that THO might be functionally
involved in mRNP biogenesis and export (23). This conclusion
is strengthened by the observation that mutants of the
Thp1Sac3 complex, which interacts with RNA and the nuclear
pore complex (NPC) and participates in mRNA export (25, 26),
confer the same transcription and hyper-recombination pheno-
types as do THO/TREX mutations (25, 27).
Sub2 is a conserved eukaryotic protein of the family of the
DEAD box RNA helicases. First identified as a protein func-
tioning at multiple steps during spliceosome assembly (28–30),
Sub2 and its human (hUAP56) and Drosophila (HEL) ortho-
logues have also been involved in mRNA transport (31–34).
Indeed, Sub2 binds in vivo to Yra1, an RNA binding protein
(35) with RNA-RNA annealing activity (36). Yra1 interacts
with the Mex67-Mtr2 mRNA export factor (32, 37), a het-
erodimer that mediates the interaction of the mRNP with the
nuclear pore complex (35, 38). A number of observation suggest
that THO may form a core complex apart from Sub2. First,
removal of Sub2 in cells does not affect the integrity of the
purified THO complex (23). Second, in a highly purified THO
complex, Sub2 is a minor component and Yra1 is absent (22).
Finally, there is an important part of Sub2 in the cell that is not
in association with the THO complex, as observed in purifica-
tion experiments using tandem affinity purification (TAP)-
tagged Sub2 (22). Despite the cumulative in vivo evidence
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indicating that THO and Sub2 mutants confer pleiotropic phe-
notypes on transcription and mRNA metabolism (17, 18, 22,
23), no direct in vitro proof exists yet that transcription elon-
gation is defective in these mutants.
To determine whether mRNA elongation was defective in
mutants of the THO/TREX complex, we performed in vitro
transcription elongation assays with two G-less cassette DNA
templates (39). In this study, we show that cell extracts of THO
complex mutants (hpr1, tho2, and mft1) and sub2 have
significantly reduced transcription elongation efficiencies in
vitro. In addition, we demonstrate that the decrease in mRNA
accumulation of hpr1 mutants is not due to an increase in
mRNA decay. It is likely that THO is not a bona fide transcrip-
tion elongation factor but rather a protein complex involved in
mRNP biogenesis during transcription elongation. Yet, our
work provides unequivocal molecular evidence that transcrip-
FIG. 1. In vitro transcription elongation assays of WCEs of wild-type and mutants of the THO/TREX complex. A, scheme of the double
G-less cassette system used for the analysis of in vitro transcription elongation. RNase T1-treatment of the mRNA driven from the GAL4-CYC1
promoter, which is activated by purified Gal4-VP16, render two fragments corresponding to the G-less cassettes. B, in vitro transcription assay of
WCEs from W303-1A (WT), RK2-6C (tho2), SChY58a (hpr1), WMK-2A (mft1), and DLY23sub2 (sub2) strains. Each reaction was stopped
after 30 min, treated with RNaseT1, and run in a 6% PAGE. Two bands from each G-less cassette were obtained, probably due to incomplete action
of RNaseT1. Efficiency of transcription elongation was determined as the percentage of total transcripts that reach the 376-nt G-less cassette in
respect to the transcripts that cover the 84-nt cassette. Radioactivity incorporated into the G-less cassettes was quantified in a Fuji FLA3000 and
normalized with respect to the C content of each G-less cassette. The mean value and S.D. of three independent experiments are shown. C, in vitro
transcription assay of WCEs from W303-1A (WT) and SChY58a (hpr1) with or without addition of the Gal4-VP16 activator to the reaction. Other
details are as described for panel B.


























tion elongation efficiency is reduced in THO/TREX mutants,
which is in agreement with the idea that transcription and
mRNA metabolism and export are coupled in the cell.
EXPERIMENTAL PROCEDURES
Yeast Strains and Plasmids—Strains used were wild-type (W303-1A)
and the isogenic mutants tho2::KAN (RK2-6D) (19), hpr1::KAN
(SChY58-a), hpr1::HIS3 (U678-1C) (17), mft1::KAN (WMK-2A) (16),
sub2::HIS3 (Ura segregant of DLY23), and sub2-201 (DLY33/sub2-
201) (28). We have also used wild-type BY4741 and its isogenic deletion
rrp6::KAN (YOR001w) (Euroscarf, Frankfurt, Germany). Strains
HRK-1A (WT), HRK-2B (rrp6::KAN), HRK-3C (hpr1::HIS3), and
HRK-44C (hpr1::HIS3 rrp6::KAN) come from genetic crosses be-
tween U678-1C and YOR001w. His6-tagged Gal4-VP16 recombinant
protein was expressed in Escherichia coli from plasmid pRJRGAL4-
VP16 (M. Ptashne, Sloan-Kettering Institute, New York, NY). We used
plasmid pGCYC1-402 (39) for in vitro transcription elongation assays
and p416GAL1lacZ (40) for expression analysis.
Preparation of Yeast Whole Cell Extracts (WCEs)—Yeast cells were
grown in rich YEPD (1% yeast extract, 2% peptone, and 2% dextrose)
medium at 30 °C to an A600 of 1. WCEs were prepared as described (41),
with the exception that the extraction buffer was 0.2 M Tris, pH 7.5, 0.39
M ammonium sulfate, 10 mM MgSO4, 20% glycerol, 1 mM EDTA, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 2.7 mM benzami-
dine, 0.3 g/ml leupeptin, and 1.4 g/ml pepstatin A. Precipitation and
dialysis were performed as described (42). WCEs were distributed in
aliquots and frozen in liquid nitrogen. They were stable after repeated
cycles of freezing and thawing.
In Vitro Transcription Assay with Whole Cell Extracts—Each reac-
tion was performed in a final volume of 40 l of buffer A 0.5 (20 mM
HEPES, pH 7.5, 20% glycerol, 1 mM EDTA, 1 mM dithiothreitol, and 500
mM potassium acetate) with 100 g of whole cell extracts and 100 ng of
Gal4-VP16 purified as described (43) and dialyzed in buffer A 0.05
(same as A 0.5 but with 50 mM potassium acetate). Final potassium
acetate concentration should be 150 mM. The reaction was set up
adding 20 l of transcription buffer (2) (final concentration was 40 mM
HEPES-KOH, pH 7.5, 5 mM MgCl2, 1 mM ATP, 1 mM GTP, 0.5 mM UTP,
0.03 mM CTP, 40 mM phosphocreatine, 32 g of creatine kinase, 5 mM
dithiothreitol, and 7.5 units of the RNase inhibitor RNAguard (Amer-
sham Biosciences)). After 20 min of preincubation at room temperature,
400 ng of pGCYC402 and 1 l of [32P]CTP (3000 Ci/mmol) were added.
The reaction was stopped at indicated times by the addition of 200 l of
stop buffer (10 mM Tris-HCl, pH 7.5, 0.3 M NaCl, and 5 mM EDTA) and
200 units of RNaseT1 for 15 min at room temperature. Samples were
treated with proteinase K, which was phenol-extracted and run in a
sequencing gel as described (44). The amount of radioactivity incorpo-
rated was quantified with a Fuji FLA3000.
In Vivo Analysis of Gene Expression and mRNA Decay—Ten micro-
grams of total RNA was prepared from induced cultures and used for
Northern analysis following standard procedures (17). DNA filters were
hybridized first with 32P-labeled DNA probes as specified. For determi-
nation of the total amount of RNA used, filters were stripped and
re-hybridized with 32P-labeled 25 S rDNA obtained by PCR as described
(17).
Miscellaneous—DNA isolation, 32P-radiolabeling, genetic crosses,
and yeast transformations were performed according to standard
procedures.
FIG. 2. In vitro transcription elongation analysis of wild-type, tho2, and hpr1 WCEs. A, time course analysis of transcription
elongation of WCEs from W303-1A (WT), RK2-6C (tho2), and SChY58a (hpr1) strains. Each reactions was stopped at the specified time, treated
with RNaseT1, and run in a 6% PAGE. B, efficiency of transcription elongation was determined as the percentage of total transcripts that reach
the downstream 376-nt G-less cassette in respect to the transcripts that cover the upstream 84-nt cassette. The mean value and S.D. of 3–4
independent experiments are shown. Other details are as described in the Fig. 1 legend.



























Whole Cell Extracts of Mutants of the THO Complex Are
Impaired in Transcription Elongation—To determine whether
mutants of the THO complex were impaired in transcription
elongation, we used our newly reported in vitro assay (39). This
assay is based on a plasmid (pGCYC1-402) in which a hybrid
GAL4-CYC1 promoter containing a Gal4 binding site is fused to
a 1.88-kb DNA fragment coding two G-less cassettes separated
by 1.4 kb. The first G-less cassette is right downstream of the
promoter and is 84-nt-long. The second is located at 1.48 kb
from the promoter and is 376-nt-long. In this assay, transcrip-
tion activated by Gal4-VP16 leads to an mRNA that, after
digestion with RNase T1, which degrades all G-containing
mRNA sequences, leaves the two G-less cassettes intact (Fig.
1A). The efficiency of transcription elongation is determined in
WCEs by the values of the ratio of accumulation of the 376-
versus the 84-nt-long G-less RNA fragments. We have recently
proved with this assay that transcription elongation is defec-
tive in spt4 WCE (39).
As can be seen in Fig. 1B, after 30 min of transcription tho2,
hpr1, and mft1 cell extracts carrying deletions of structural
genes of the THO complex fully transcribed the 376-nt G-less
cassette with efficiencies ranging from 58 to 71% of the wild-
type levels. These results indicate that removal of any subunit
of the THO complex leads to a similar reduction in the effi-
ciency of transcription elongation in vitro. To determine
whether or not the addition of Gal4-VP16 could affect tran-
scription elongation in wild-type and THO mutants differently,
we repeated the experiments in the absence and the presence of
externally added Gal4-VP16. We first showed that, as expected,
transcription initiation efficiency in the absence of Gal4-VP16,
as determined by the accumulation of the 84-nt G-less cassette,
was lower (22%) than in the presence of Gal4-VP16. Further-
more, as can be seen in Fig. 1C, the addition of Gal4-VP16
diminished the efficiency of transcription elongation similarly
in hpr1 and wild-type cells. Therefore, the lower efficiency of
transcription elongation observed in the THO mutants is inde-
pendent of the transcription activator.
To further demonstrate that elongation was less efficient in
mutants of the THO complex, we determined the kinetics of
transcription elongation in time course experiments in mu-
tants of the two largest subunits of the complex, tho2 and
hpr1. As can be seen in Fig. 2, transcription elongation effi-
ciency in both mutant extracts was 46–66% of the wild-type,
depending on the time the reaction was run. We conclude that
THO complex depletion causes a deficiency of transcription
elongation in whole cell extracts. It is worth noting that this
deficiency is independent of the growth rate of the strains
tested, because whereas mft1 cells grow like wild-type cells
and hpr1 cells grow poorly, both mutations have similar ef-
fects on transcription elongation.
Whole Cell Extracts of Mutants of Sub2 Show Transcription
Elongation Impairment—The THO complex is associated with
proteins involved in mRNA export, such as Sub2 and Yra1, in
a larger complex termed TREX. However, THO may form a core
complex apart from Sub2 (22). This, together with the fact that
FIG. 3. In vitro transcription analysis of wild-type and sub2-201 WCEs. Time course analysis of transcription elongation of WCEs from
W303-1A (WT) and DLY33sub2-201 (sub2-201) strains unheated or heated for 15 min at 37 °C before being added to the reaction. Reactions were
stopped at the indicated times, incubated with RNaseT1, and run in a 6% PAGE. Other details are as described in the Figs. 1 and 2 legends.


























Sub2 and Yra1 are proteins with functional roles in mRNA
splicing and/or mRNA export, makes it important to know
whether Sub2 is also required for efficient transcription
elongation.
We applied in vitro transcription analysis to sub2 mutants.
As can be seen in Fig. 1B, after 30 min of transcription, sub2
WCEs fully transcribed the 376-nt G-less cassette with 36% of
the efficiency of the wild-type. To get further evidence of the
role of Sub2 in transcription elongation, we determined the
kinetics of transcription elongation of whole cell extracts with
time course experiments using WCEs of the sub2-201 mutant.
It has been reported that the sub2-201 mutation causes a
splicing phenotype at 37 °C in WCEs in vitro that is not ob-
served at the permissive temperature (28). Elongation assays
were performed by maintaining the WCEs at 23 °C (unheated)
or shifting them to 37 °C for 15 min (heated) immediately
before starting the experiment. As can be seen in Fig. 3, tran-
scription elongation was reduced in unheated WCEs (54% of
the wild-type levels after 40 min), indicating that sub2–101 was
leaky at the permissive temperature for transcription elonga-
tion. However, the reduction in transcription elongation effi-
ciency was stronger in heated sub2-201 WCEs in which the
elongation levels were similar to those of sub2 cells (30% of
the wild-type levels). This result indicates that Sub2 is re-
quired for efficient elongation.
The Gene Expression Defect of hpr1 Is Not Due to an In-
crease in mRNA Decay—Recently, the question has been raised
of whether the low mRNA levels observed in vivo in mutants of
the THO/TREX complex could be due to a higher rate of mRNA
degradation and not to a transcription defect (37, 45). It was
previously observed that steady-state levels of lacZ mRNA
driven from a GAL10 promoter in yra1–8 rrp6 mutants were
2–3-fold higher than those in yra1–8 mutants (37). Also, the
5 end of HSP104 mRNA accumulates 2 times above the
3-end in hpr1 and sub2-201 single mutants but not in hpr1
rrp6 and sub2-201 rrp6 double mutants (45). However, these
differences are very low as compared with the 20-fold decrease
in expression of genes such as lacZ observed in time course
experiments (16) and do not explain the gene expression and
recombination phenotypes of THO mutants.
We decided to assay whether the gene expression defects of
THO/TREX mutants reflected transcription defects rather
than higher mRNA degradation rates. We measured the half-
life of two differently affected mRNAs in THO mutants, i.e. the
lacZ and GAL1 mRNAs, both driven from the GAL1 promoter.
It was shown previously that lacZ was poorly expressed in vivo
in THO mutants, whereas GAL1 levels of expression were
proximal to wild-type levels (16, 17). As can be seen in Fig. 4, A
and B, hpr1 and wild-type cells have similar kinetics of deg-
radation of both lacZ and GAL1 mRNAs. Indeed, we do not
detect higher levels of mRNA stability in rrp6 mutants (Fig.
4C). That is, mRNA stability is the same in both wild-type and
mutant strains, regardless of whether or not the expression of
the mRNA analyzed was affected by hpr1. Therefore, failure
of the hpr1 mutant and, by extension, THO/TREX mutants to
accumulate mRNAs such as lacZ in vivo (17) was not due to an
increase in mRNA decay but to low levels of transcript forma-
tion. This is consistent with the transcription elongation defect
detected in vitro. The prediction of this result is that rrp6
should not significantly suppress the defect in the kinetics of
accumulation of lacZ mRNA caused by hpr1. As expected, Fig.
5 shows similar kinetics of transcription in hpr1 and hpr1
rrp6 strains that, in both strains, occur at 42 and 22% of the
wild-type levels after 1 h of induction, respectively.
DISCUSSION
Using an in vitro transcription elongation assay based on
supercoiled DNA templates containing two G-less cassettes, we
provide molecular evidence that the THO/TREX complex, with
a role at the interface between transcription and mRNA export,
FIG. 4. Kinetics of degradation of
lacZ and GAL1 mRNAs in hpr1 and
wild-type cells. A, Northern analysis of
lacZ mRNA decay in wild-type (W303-1A)
and hpr1 (U678-1C) cells. Mid-log phase
cultures of wild-type and hpr1 cells har-
boring p416GAL1lacZ were grown in 2%
galactose synthetic medium for 3 h and
transferred to 2% glucose-synthetic me-
dium before samples were taken. B,
Northern analysis of mRNA decay from
endogenous GAL1 transcripts. Experi-
ments were performed as described for
panel A. C, Northern analysis of the lacZ
mRNA decay in isogenic BY4741 (WT)
and YOR001w (rrp6) strains trans-
formed with p416GAL1lacZ. Experiments
were performed as described for panel A.
The 0.75-kb PvuII-AvaI internal GAL1
fragment, the 3-kb BamHI-BglII lacZ
fragment, and an internal 589-bp 25 S
rRNA fragment obtained by PCR were
used as 32P-labeled DNA probes. North-
ern blots were quantified in a Fuji FLA
3000. RNA levels are given in arbitrary
units normalized with respect to the
rRNA levels of each sample.


























is required for transcription elongation. The different mutants
of the THO core complex (hpr1, tho2, and mft1) and sub2
and sub2-201 showed inefficient transcription elongation in
vitro, consistent with previously reported in vivo mRNA accu-
mulation defects. We excluded experimentally the possibility
that the mRNA expression defect of hpr1 mutants and, by
extension, THO/TREX mutants, was due to high mRNA deg-
radation rates.
Several results suggest that THO has a role in mRNP bio-
genesis and export. First, the tandem affinity purification-
tagged THO complex copurified with mRNA export proteins
Sub2 and Yra1 (22). Second, mutants of the mRNA export
factors Sub2, Yra1, Mex67, Mtr2, Thp1, and Sac3 showed tran-
scription-dependent hyper-recombination and gene expression
phenotypes like those of THO mutants (23–25,27). Third, THO
mutants are affected in mRNA export (22, 46). It was therefore
important to prove that the gene expression defect observed in
mutants of the THO complex was the result of an impairment
of transcription elongation. Our in vitro transcription elonga-
tion assay unequivocally shows that, regardless of its particu-
lar function, THO is required for efficient transcription elon-
gation. In an assay designed to specifically quantify
transcription elongation efficiency, the hpr1, tho2, and
mft1 mutants of the THO complex reduced the efficiency of
transcription elongation to 58–71% of the wild-type levels
(Figs. 1 and 2).
THO does not have an effect on the rate of mRNA decay that
could explain the differences of gene expression of THO mu-
tants (Figs. 4 and 5). Degradation rates of mRNAs are the same
in hpr1 and wild-type mutants, regardless of whether or not
expression of the gene studied (lacZ or GAL1) was negatively
affected by hpr1 (Fig. 4). In addition, rrp6, a null mutation
of the Rrp6 exoribonuclease component of the nuclear exosome,
does not significantly suppress the lacZ expression defect
caused by hpr1. As expected from this result, rrp6 does not
suppress the hyper-recombination phenotype of hpr1 mu-
tants.2 Our mRNA stability results are consistent, therefore,
with the in vitro analysis showing a defect in transcription
elongation and with the hallmark phenotype of THO mutants,
a transcription elongation-dependent hyper-recombination.
Sub2 is a putative RNA helicase of the DEAD box family that
has been shown to have a role in mRNA splicing and export (28,
29, 31–33). In our transcription elongation assays, sub2 confers
a reduction in transcription elongation efficiency of 30–36% of
the wild-type levels (Figs. 1 and 3). This proves clearly that
Sub2 is also required for efficient transcription elongation in
vitro. Examples of the stimulatory effects of proteins involved
in mRNA metabolism, such as splicing proteins, on transcrip-
tion elongation has been reported previously. Thus, in HeLa
cell extracts, specific U1 and U2 small nuclear RNPs and Sm
splicing proteins are loaded onto the transcription machinery
via positive transcription elongation factor b (P-TEFb) interac-
tion and are necessary for efficient transcription elongation
(47). As shown previously for mRNA export activity, the Sub2
requirement for transcription elongation is splicing-indepen-
dent. This conclusion is based on two pieces of evidence. First,
the elongation defect is observed in an intron-free system (dou-
ble G-less cassette). Second, at permissive temperatures sub2-
201 extracts are splicing-proficient (28), but transcription is
elongation-deficient (Fig. 3).
The observation that transcription elongation in heat-inac-
tivated sub2-201 extracts is more severely impeded than in
THO mutant extracts indicates that Sub2 might be a key
element in facilitating transcription elongation. This supports
the idea that Sub2-Yra1 and THO represent two distinct sub-
complexes of TREX. It has been hypothesized that THO may be
loaded onto RNAPII-mRNP structures prior to Sub2, helping to
recruit it (22, 37). This is in accordance with our in vitro results
and the observations that multicopy sub2 suppresses both the
2 P. Huertas and A. Aguilera, unpublished results.
FIG. 5. Expression analysis of GAL1pr::lacZ construct in HRK-1A (WT), HRK-2B (hpr1), and HRK-44C (hpr1 rrp6) congenic
strains. A, -galactosidase activity of strains transformed with plasmid p416GAL1lacZ. Each value represents the average of two different
transformants. Only the data of induced expression (2% galactose) are given. Under repression conditions (2% glucose), values were below detection
levels in all cases. U, units. B, Northern analysis of lacZ mRNA driven from the GAL1 promoter and GAL1 endogenous locus. Mid-log phase
cultures of cells transformed with plasmid p416GAL1lacZ were diluted in synthetic complete (SC) 3% glycerol-2% lactate media lacking uracil to
an A600 of 0.5 and incubated for 16 h at 30 °C. 2% galactose was then added, and samples were taken at different times, as specified. Other details
are as described in the Fig. 4 legend. AU, arbitrary units.


























transcription and recombination phenotypes of hpr1 cells
(23, 24).
The negative effect on transcription elongation of the THO/
TREX mutations does not necessarily indicate that THO or
Sub2-Yra1 are bona fide transcription elongation factors (48).
In this sense, spt4 mutants show similar in vitro and in vivo
transcription elongation defects as do THO mutants. However,
in contrast to THO mutants, in spt4 cells the in vitro tran-
scription elongation defect is stronger; impairment of tran-
scription does not lead to hyper-recombination, and there are
no mRNA export defects (39). The interconnection between the
different steps of mRNA metabolism from transcription to
mRNA processing and export (49) suggests the possibility that
a set of proteins without a primary role in transcription may
also affect transcription elongation. Consistent with this view,
mutations in the Mex67Mtr2 and Thp1Sac3 complexes confer
similar transcription and recombination phenotypes as the
THO mutants do (23, 25, 27). The effect of THO and Sub2 on
transcription elongation and mRNA metabolism and export
suggests the possibility, already raised, that the nascent
mRNA might have a role in transcription elongation efficiency
and transcription-associated hyper-recombination (48).
In summary, this study shows that there is a set of conserved
eukaryotic factors, like THO/TREX, that function at the inter-
face between transcription and mRNA metabolism and that,
regardless of their specific functional roles, are required for
efficient transcription elongation. Deciphering the function of
these factors will contribute to understanding the mechanisms
of transcription elongation, how it is coupled with mRNA proc-
essing and export, and the mechanisms of transcription-asso-
ciated genetic instability.
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